Research graph
References from GLP1R expression and Parkinson’s disease and related disorders in GLP-1 receptor agonist-treated type 2 diabetes. Local targets link to admitted publications; unresolved targets remain external evidence.
Parkinson disease
10.1038/nrdp.2017.13 · 2017 · External reference
Diagnosis and treatment of Parkinson disease: A review
10.1001/jama.2019.22360 · 2020 · External reference
Clinical aspects of the differential diagnosis of Parkinson's disease and parkinsonism
10.3988/jcn.2022.18.3.259 · 2022 · External reference
Glucagon-like peptide 1 in health and disease
10.1038/s41574-018-0016-2 · 2018 · External reference
GLP-1 programs the neurovascular landscape
10.1016/j.cmet.2024.09.003 · 2024 · External reference
Glucagon-like peptide-1 receptor: Mechanisms and advances in therapy
10.1038/s41392-024-01931-z · 2024 · External reference
Block of A1 astrocyte conversion by microglia is neuroprotective in models of Parkinson's disease
10.1038/s41591-018-0051-5 · 2018 · External reference
Insulin resistance and exendin-4 treatment for multiple system atrophy
10.1093/brain/awx044 · 2017 · External reference
GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism
10.1073/pnas.0806720106 · 2009 · External reference
Diabetes medications and risk of Parkinson's disease: A cohort study of patients with diabetes
10.1093/brain/awaa262 · 2020 · External reference
Glucagon-like peptide-1 receptor agonists and risk of Parkinson's disease in patients with type 2 diabetes: A population-based cohort study
10.1002/mds.29992 · 2024 · External reference
Exenatide once a week versus placebo as a potential disease-modifying treatment for people with Parkinson's disease in the UK: A phase 3, multicentre, double-blind, parallel-group, randomised, placebo-controlled trial
10.1016/s0140-6736(24)02808-3 · 2025 · External reference
Trial of lixisenatide in early Parkinson's disease
10.1056/nejmoa2312323 · 2024 · External reference
Safety, tolerability, and efficacy of NLY01 in early untreated Parkinson's disease: A randomised, double-blind, placebo-controlled trial
10.1016/s1474-4422(23)00378-2 · 2024 · External reference
Human GLP1R variants affecting GLP1R cell surface expression are associated with impaired glucose control and increased adiposity
10.1038/s42255-023-00889-6 · 2023 · External reference
GLP1R gene expression and kidney disease progression
10.1001/jamanetworkopen.2024.40286 · 2024 · External reference
Genomic data in the All of Us Research Program
10.1038/s41586-023-06957-x · 2024 · External reference
The “All of Us” research program
10.1056/nejmsr1809937 · 2019 · External reference
10.1101/2025.03.14.24319455
10.1101/2025.03.14.24319455 · External reference
Whole-genome sequencing of 490,640 UK biobank participants
10.1038/s41586-025-09272-9 · 2025 · External reference
Unresolved reference
External reference
GLP-1RA and SGLT2i medications for type 2 diabetes and Alzheimer disease and related dementias
10.1001/jamaneurol.2025.0353 · 2025 · External reference
Inflammation and immune dysfunction in Parkinson disease
10.1038/s41577-022-00684-6 · 2022 · External reference
Targeting innate immune mediators in type 1 and type 2 diabetes
10.1038/s41577-019-0213-9 · 2019 · External reference
Aberrations in peripheral inflammatory cytokine levels in Parkinson disease: A systematic review and meta-analysis
10.1001/jamaneurol.2016.2742 · 2016 · External reference
The immunological genome project: Networks of gene expression in immune cells
10.1038/ni1008-1091 · 2008 · External reference
Divergent roles for the gut intraepithelial lymphocyte GLP-1R in control of metabolism, microbiota, and T cell-induced inflammation
10.1016/j.cmet.2022.08.003 · 2022 · External reference
Glucagon-like peptide 1 improves insulin resistance in vitro through anti-inflammation of macrophages
10.1590/1414-431x20165826 · 2016 · External reference
Central glucagon-like peptide 1 receptor activation inhibits toll-like receptor agonist-induced inflammation
10.1016/j.cmet.2023.11.009 · 2024 · External reference
Glucagon-like peptide-1 strengthens the barrier integrity in primary cultures of rat brain endothelial cells under basal and hyperglycemia conditions
10.1007/s12031-015-0696-1 · 2016 · External reference
Exendin-4 reverses biochemical and functional alterations in the blood-brain and blood-CSF barriers in diabetic rats
10.1007/s12035-016-9798-1 · 2017 · External reference
Multiple system atrophy
10.1038/s41572-022-00382-6 · 2022 · External reference
Peripheral immune profile and neutrophil-to-lymphocyte ratio in progressive supranuclear palsy: Case-control study and meta-analysis
10.1111/ene.16451 · 2024 · External reference
Laboratory prognostic factors for the long-term survival of multiple system atrophy
10.1038/s41531-022-00413-9 · 2022 · External reference
Exenatide once weekly versus placebo in Parkinson's disease: A randomised, double-blind, placebo-controlled trial
10.1016/s0140-6736(17)31585-4 · 2017 · External reference
Cardioprotective glucose-lowering agents and dementia risk: A systematic review and meta-analysis
10.1001/jamaneurol.2025.0360 · 2025 · External reference
Activation of AMPK by GLP-1R agonists mitigates Alzheimer-related phenotypes in transgenic mice
10.1038/s43587-025-00869-3 · 2025 · External reference
Lixisenatide reduces amyloid plaques, neurofibrillary tangles and neuroinflammation in an APP/PS1/tau mouse model of Alzheimer's disease
10.1016/j.bbrc.2017.11.114 · 2018 · External reference
